Oxolamine (citrate)
Oxolamine (citrate) structure
|
Common Name | Oxolamine (citrate) | ||
|---|---|---|---|---|
| CAS Number | 1949-20-8 | Molecular Weight | 437.44400 | |
| Density | 1.066g/cm3 | Boiling Point | 364.8ºC at 760 mmHg | |
| Molecular Formula | C20H27N3O8 | Melting Point | 153-154ºC | |
| MSDS | Chinese USA | Flash Point | 174.4ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
[Therapeutic action of oxolamine in acute tracheo-bronchitis].
Clin. Ter. 100(5) , 485-92, (1982)
|
|
|
Hallucinations in children caused by oxolamine citrate.
Med. J. Aust. 150(8) , 449-50, 452, (1989) Twenty reports in Australia, Belgium and The Netherlands have implicated oxolamine-citrate cough-mixtures as a cause of hallucinations in children of less than 10 years of age. Fever is not thought to be a likely alternative explanation. Similar reactions in ... |
|
|
Sustained-release dosage form of oxolamine citrate: preparation and release kinetics.
J. Microencapsul. 9(2) , 167-72, (1992) One of the principal uses of microencapsulation for pharmaceuticals has been the preparation of sustained-release dosage forms which have been usually presented in the form of a suspension or gel. However, a non-disintegrating tablet would be a better formula... |
|
|
Effect of oxolamine on cough sensitivity in COPD patients.
Respir. Med. 96(1) , 61-3, (2002)
|
|
|
Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats.
Biopharm. Drug Dispos. 28(3) , 125-33, (2007) The possible reason for the significantly greater AUC of oral warfarin with oral oxolamine in male Sprague-Dawley rats was evaluated. After oral administration of warfarin at a dose of 2 mg/kg to male rats with oxolamine at doses of 10 and 50 mg/kg, the AUC v... |
|
|
[The use of guacetisal in chronic obstructive bronchopneumopathy. Controlled clinical study].
Minerva Med. 72(7) , 355-62, (1981) A single-blind, between-patients trial was run to compare the fluidifying, expectorant, antitussive, antipyretic and anti-inflammatory activity, and the local and systemic tolerance of guacetisal, an active principle obtained by the esterification of acetylsa... |